Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
3 days ago · BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an ...
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store JOURNAVX? Store JOURNAVX at room temperature between 68ºF to 77ºF (20ºC to 25ºC). Keep JOURNAVX and all medicines out of the reach of children. General information about the safe and effective use of JOURNAVX.
FDA Approves Novel Non-Opioid Treatment for Moderate to …
2 days ago · The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
FDA Approves Journavx - Drugs.com
FDA Approves Journavx BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Journavx ™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
What to Know About Journavx, the Non-Opioid Pain Medication …
1 day ago · The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. ... According to the FDA, Journavx “reduces pain by ...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
2 days ago · BOSTON, January 30, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non ...
FDA approves first new type of pain medication in 25 years
2 days ago · It will be sold under the brand name Journavx. A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. ... acting director of the FDA ...
FDA Approves Journavx, First New Non-Opioid Pain Pill in Decades
2 days ago · FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin. The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury, the Associated Press reported.
FDA Approves Journavx Drug to Treat Pain Without Addiction Risk
2 days ago · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat ...
Journavx: Uses, Dosage, Side Effects, Warnings - Drugs.com
2 days ago · Journavx FDA approval was received on January 30, 2025, for treating moderate to severe acute pain in adults. This approval was based on positive results from Phase 3 clinical trials (VX21-548-101 and VX21-548-102), which showed that it effectively reduced acute pain for 48 hours after surgery.
- Some results have been removed